Pharmacogenomic landscape of TNF inhibitors in the Middle Eastern Qatari population
The findings of this study will enhance our understanding of the pharmacogenomics of TNF inhibitors in Qatar and beyond, while also supporting the study of genetics in underrepresented populations.
Authors
- Karima Becetti (ORCID: https://orcid.org/0000-0002-0715-2993)
- Georges Nemer (ORCID: https://orcid.org/0000-0003-2157-5279)
- Sanaa Sharari
- Ehsan Pourkarimi (ORCID: https://orcid.org/0000-0001-9598-3465)
- Nady El Hajj (ORCID: https://orcid.org/0000-0003-3420-8531)
- Farah El Assadi (ORCID: https://orcid.org/0000-0001-7145-5473)
- Nour Hamad
- Mamoun Elawad (ORCID: https://orcid.org/0000-0003-3014-0680)
- Zainab Jan (ORCID: https://orcid.org/0000-0002-4050-8496)
- N Ibrahim
- Dinesh Velayutham (ORCID: https://orcid.org/0000-0002-9425-7266)
- M. Hammoudeh (ORCID: https://orcid.org/0000-0002-3313-2769)
- Omar Albagha (ORCID: https://orcid.org/0000-0001-5916-5983)
- Samar Al Emadi
- Hala Albakheet
- Mona El Chawli
- Sharon Bout-Tabaku
- Buthaina Al Adba
- Fathima Abubacker
Institutions
- University of Liverpool (GB)
- Queen Mary University of London (GB)
- Hamad bin Khalifa University (QA)
- William Harvey Research Institute (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1674889
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hamad Bin Khalifa University
- Khalifa University of Science, Technology and Research
- Qatar National Research Fund